Chronic Heart Failure Updates at ACC 2022: Important New Findings for HFrEF and HFpEF*

Download All
April 2-4, 2022; Washington, DC
Review the latest data in managing HFrEF and HFpEF with a Capsule Summary and expert-authored commentaries covering key studies and updates from ACC 2022.

ACC 2022: Research Advances in HFrEF and HFpEF

Capsule Summary Slidesets

In patients with HFpEF, sacubitril/valsartan attenuated the rate of decline in renal outcomes similarly in patients with and without diabetes compared to valsartan alone.

Released: April 6, 2022

In ambulatory patients with heart failure, low-sodium diet showed a modest quality-of-life benefit and improvement in NYHA class, but no improvement in all-cause mortality or CV-related hospitalizations.

Released: April 6, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings